---
schema_version: "secwatch.filing_event.v1"
accession: "0001819790-23-000081"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:28:20.483443+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tarsus reports Q3 net loss $39.1M; XDEMVY launch yields $1.7M in 5 weeks

## Summary
- Net product sales of XDEMVY were $1.7M with ~1,700 bottles dispensed in first 5 weeks post-launch.
- Net loss of $39.1M ($1.28 per share) vs. $22.5M loss ($0.84) in Q3 2022; SG&A rose to $30.3M on launch costs.
- Gross-to-net discount on XDEMVY was 73%, better than anticipated; cash, equivalents and marketable securities $246.9M.
- Received $99.4M net proceeds from August 2023 public equity offering; balance sheet strengthened.
- XDEMVY added to AAO Preferred Practice Pattern guidelines as first FDA-approved therapy for Demodex blepharitis.

## SEC filing metadata
- accession: 0001819790-23-000081
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000181979023000081/0001819790-23-000081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000181979023000081/tars-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001819790-23-000081
- JSON: https://secwatch.observer/filing/0001819790-23-000081.json
- Plain text: https://secwatch.observer/filing/0001819790-23-000081.txt

## Key facts
- Earnings Releases
  Tarsus Pharmaceuticals, Inc. reported the third quarter ended September 30, 2023 results: revenue $1.9 million, net income $(1.28), EPS $(1.28).
  - Period: the third quarter ended September 30, 2023
  - Revenue: $1.9 million
  - Net income: $(1.28)
  - EPS: $(1.28)
  - Result: reported results
  source text: Gland Disease ● TP-04 Topline Phase 2a (Galatea) Rosacea ● TP-05 Topline Phase 2a (Carpo) Lyme Disease Prevention ● Third Quarter 2023 Financial Results • Total revenues were $1.9 million, driven primarily by $1.7 million in net product sales, representing five weeks of sales following the launch of XDEMVY in late August. • Cost of sales were $0.4 million, due
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000181979023000081/0001819790-23-000081-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.